Get started

Coronasvirus

Corona death analyses in GermanyWelcome to my Corona Death Analysis *Note because the chart was inserted as an image, the scaling may have shifted slightly, simply scale at the right edge until the orange zero matches the zero line of the chart. First of all, I know Corona is a delicate subject and also that I analyze the deaths here seems to work a macabre, but the fact is that the numbers are rising and this can have an impact on the German economy, this analysis serves as a complement to my DAX short analysis and is purely scientific nature. The Dax analysis can be found here (German Only) Let's get to the analysis: As we can see from the chart, deaths increased rapidly between January and February, reaching a high of ca 1138. In February, a bearish SKS formed at the high which had also already reached its target of 371 deaths. This target line is very often reached again after the Unterstreiten in later upward movements or correction phases and serves us thus as a first "target line" Furthermore, we can take from the chart an ABC Correct which has the following death numbers as a target. Target 1 435 Target 2 705 Target 3 900 Target 4 1451 Target 5 1846 Here the death number of 900 is to be seen as the first strong resistance. At 1451 I expect the end of the rising numbers for the first time, whereas 1846 deaths would be the maximum and at the latest here a trend reversal should take place. If you liked this idea, I would be pleased about a click on the Like button ;) If you have any questions, suggestions or a different opinion, don't be afraid to use the comment function. Thanks a lot Disclaimer: Please keep in mind that this is a pure analysis and only reflects what my eye shows me ;) This analysis is for informational purposes only and is scientific in nature. This analysis is not based on any fundamental data! This analysis is not an investment advice and should not be considered as a buy, sell or hold signal. Always do your own research before investing and seek the advice of a qualified person. I am not an investment advisor or similar and do not make any investment recommendation here.
TSE:5909Long
by Highrisk221
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech. In fact, over 30% of Vaxart stock has been sold short. Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use. At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week. Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart. Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS). Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat. Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about. With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate. Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
NASDAQ:VXRT
by AlenCiken
Short US marketUS cases climbed by 13,000 to 68,000 cases (stats from worldometer site) already and it seems like the rally 2 days ago just took a small turn downwards. I still think it will continue heading downwards till either vaccine is released or when the numbers are better controlled. Because looking at the growth rate, it doesn't look like its slowing down and many countries have started partial shutdowns and I think the impact on their economy will be huge but the real effect on the economy can only be seen at a later stage.
CShort
by Trader_hao